In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Beyondspring (BYSI), with a price target of $41.00. The company’s shares closed last Monday at $14.24.
According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.6% and a 24.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
Currently, the analyst consensus on Beyondspring is a Strong Buy with an average price target of $29.50, an 114.2% upside from current levels. In a report issued on March 18, William Blair also reiterated a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Beyondspring’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $9.37 million. In comparison, last year the company had a GAAP net loss of $14.93 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.
